This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

FLEXISEQ® Wins BVDA Innovation Of 2013 Award: Innovative New Treatment For The Symptoms Of Osteoarthritis

FRANKFURT, Germany and LONDON, February 4, 2013 /PRNewswire/ --

The Federal Association of German Pharmacists (BVDA)  today presented its "Innovation Award 2013" to FLEXISEQ®, an innovative new treatment for pain and stiffness associated with osteoarthritis (OA).

The BVDA president, and pharmacist Thomas Hieble, explained; "The jury awarded the prize to FLEXISEQ® in recognition of the application of its innovative Sequessome Technology® to deliver symptom relief to sufferers of OA. The technology incorporates highly flexible phospholipid vesicles which can penetrate the skin and into the affected joint below. Once inside the joint, they accumulate on the surface of the cartilage to lubricate it. The result: pain relief and increased joint mobility - achieved conveniently and without the risk of the well recognised, systemic side effects associated with drugs typically used for the treatment of OA."

In their latest editions, various renowned medical journals such as "Ärzte Zeitung" and the "Zeitschrift für Rheumatologie" reported on this medical advance.

FLEXISEQ has an innovative mode of action due to its use of Sequessome Technology and its convenient gel formulation enables patients to self administer FLEXISEQ topically to the affected joint. The Sequessome™ vesicles contained within are proven to enter the synovial joint after application and increase phospholipid levels in the synovial fluid where they are known to be depleted in joints affected by OA. This physical, mode of action reduces the pain, (in phase III clinical trials, as effectively as the frequently prescribed oral drug medicine - celecoxib) and also improves joint mobility, thereby giving easier movement to patients.

Hundreds of millions of people worldwide suffer from OA, a chronic joint disease which makes the lives of those affected permanently more difficult. According to the Robert Koch Institute, the likelihood of contracting OA increases dramatically with age.

1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!


DOW 17,826.30 -279.47 -1.54%
S&P 500 2,081.18 -23.81 -1.13%
NASDAQ 4,931.8150 -75.9760 -1.52%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs